Status | Study |
Completed |
Study Name: Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults Condition: Hemorrhagic Fever, Ebola Date: 2015-09-29 Interventions: Biological: HPIV3-EbovZ GP Vaccine Administered intranasally by a VaxINator device |
Completed |
Study Name: An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection Condition: Parainfluenza Date: 2013-07-11 Interventions: Drug: DAS181-F02 Dry Powder in Bulk |
Active, not recruiting |
Study Name: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen Condition: Parainfluenza Date: 2012-07-17 Interventions: Drug: DAS181 dry powder, formulation F02 D |
Withdrawn |
Study Name: DAS181 in Patients With Parainfluenza Condition: Parainfluenza Infection Date: 2011-09-24 Interventions: Drug: DAS181 20 mg per day of |
Completed |
Study Name: Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children Condition: Parainfluenza Virus 3, Human Date: 2010-12-02 Interventions: Biological: rHPIV3cp45 Vaccine |
Active, not recruiting |
Study Name: The Respiratory Protection Effectiveness Clinical Trial Condition: Influenza Respiratory Syncytial Viruses Date: 2010-11-29 Interventions: Device: N95 Respirator Partici |
Completed |
Study Name: Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants Condition: Human Parainfluenza Virus 2 Date: 2010-06-07 Interventions: Biological: Standard Dose HPIV2 Vaccine |
Completed |
Study Name: Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children Condition: Paramyxoviridae Infections Virus Diseases Date: 2009-11-25 Interventions: Drug: rHPIV3cp45 10^5 TCID50 n |
Completed |
Study Name: Surveillance Study of Viral Infections Following Lung Transplantation Condition: Lung Transplantation Bronchiolitis Obliterans Epstein-Barr Date: 2008-06-17 |
Completed |
Study Name: A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants Condition: Healthy Date: 2008-05-23 Interventions: Biological: MEDI-534, Cohort 1 |